Filing Flows › Pacific Biosciences of California (PACB) › Q2 2026
Pacific Biosciences of California (PACB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Pacific Biosciences of California (PACB) reported revenue of $39.0M for the second quarter 2026 (Q2 2026), -2% from a year earlier and +5% from the quarter before. Operating margin was -114.4%, net loss $44.7M (114.7% of revenue).
Pacific Biosciences of California, Q2 2026: revenue $39.0M (-2% year over year), operating margin -114.4%, net loss $44.7M, operating cash flow −$35.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $39.0M | +5% | -2% |
| Operating profit | −$44.6M | — | — |
| Net earnings | −$44.7M | — | — |
| Operating cash flow | −$35.6M | — | — |
What changed
Revenue was $39.0M in Q2 2026, down 2% year over year and up 5% from the previous quarter. Consumable revenue was the largest line at 52% of revenue. Instrument revenue lost $1.3M year over year (down 9%), 173% of the total change.
Gross margin was 32.4%, down 4.5 points from Q2 2025. Operating costs exceeded revenue by $44.6M, an operating margin of -114.4%. Operating expenses fell 4% while revenue fell 2%. The quarter ended with a net loss of $44.7M, wider than the previous quarter's $8.3M loss.
Operating cash flow was −$35.6M. Non-cash charges added back $2.3M of depreciation and $9.3M of share-based compensation. Working capital and other items used $2.4M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$37.1M.
Questions
What was Pacific Biosciences of California's revenue in the second quarter 2026?
Pacific Biosciences of California (PACB) reported revenue of $39.0M for the second quarter 2026 (Q2 2026), -2% from a year earlier and +5% from the quarter before.
Was Pacific Biosciences of California profitable in the second quarter 2026?
Operating loss was $44.6M (-114.4% of revenue) and net loss $44.7M.
Source: Pacific Biosciences of California 10-Q on SEC EDGAR.